Episode

Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA

Podcast: The IMID Forum
Published: Nov 27, 2025
Duration seconds: 585
Processing state: not_requested
Canonical source: https://soundcloud.com/imidforum/discussing-ra-real-world-evaluation-of-jaki-efficacy-persistence-and-cardiovascular-safety-in-ra
Audio: https://feeds.soundcloud.com/stream/2219750762-imidforum-discussing-ra-real-world-evaluation-of-jaki-efficacy-persistence-and-cardiovascular-safety-in-ra.mp3
JSON: /v1/public/podcasts/the-imid-forum-981476/episodes/discussing-ra-real-world-evaluation-of-jaki-efficacy-persistence-and-cardiovascular-safety-in-ra
Markdown: /podcast/the-imid-forum-981476/discussing-ra-real-world-evaluation-of-jaki-efficacy-persistence-and-cardiovascular-safety-in-ra.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-ra-real-world-evaluation-of-jaki-efficacy-persistence-and-cardiovascular-safety-in-ra/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-ra-real-world-evaluation-of-jaki-efficacy-persistence-and-cardiovascular-safety-in-ra.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.